Secondary Logo

Effects of depression and anxiety on antiretroviral therapy adherence among newly diagnosed HIV-infected Chinese MSM

Tao, Jun; Qian, Han-Zhu; Kipp, Aaron M.; Ruan, Yuhua; Shepherd, Bryan E.; Amico, Kathy Rivet; Shao, Yiming; Lu, Hongyan; Vermund, Sten H.

doi: 10.1097/QAD.0000000000001287
EPIDEMIOLOGY AND SOCIAL
Free

Objective: Our objective was to explore the effect of depression and anxiety on adherence to antiretroviral therapy (ART) among MSM with newly diagnosed HIV infections.

Design: We conducted a prospective study of Chinese MSM with newly diagnosed HIV infections.

Methods: The Hospital Anxiety and Depression Scale was used to measure depression and anxiety at baseline, 6 and 12 months, separately. ART adherence was self-reported once every 3 months (‘perfect’ or no missing dose in the past 3 months vs. ‘imperfect’ adherence or at least one missing dose in the past 3 months). We utilized a priori substantial knowledge guided by causal models to identify confounding covariates, and performed mixed-effect logistic regression to assess the effects of depression and anxiety on ART adherence.

Results: We included 228 participants who initiated ART after HIV diagnosis and before the end of study. A one-unit increase in the depression and anxiety score was associated with a 16% increase [adjusted odds ratio (aOR), 1.16; 95% confidence interval (CI), 1.02–1.32] and a 17% increase (aOR, 1.17; 95% CI, 1.03–1.33) in the odds of reporting imperfect ART adherence, respectively. When depression and anxiety were categorized (normal, borderline, and likely), only likely anxiety had a significant association with imperfect ART adherence (aOR, 4.79; 95% CI, 1.12–20.50).

Conclusion: Depression and anxiety are risk factors for imperfect ART adherence among Chinese MSM with newly diagnosed HIV infections. Intensive intervention on depression and/or anxiety beyond regular post-HIV-testing counseling may increase adherence to ART, and improve HIV treatment outcomes.

aVanderbilt Institute for Global Health

bDivision of Epidemiology, Departments of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

cState Key Laboratory of Infectious Disease Prevention and Control (SKLID), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China

dDepartments of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

eDepartment of Health Behavior and Health Education, University of Michigan, Ann Arbor, Michigan, USA

fBeijing Center for Disease Control and Prevention, Beijing, China

gDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Correspondence to Sten H. Vermund, MD, PhD, 2525 West End Avenue, Suite 750, Nashville, Tennessee 37203, USA. Tel: +1 615 322 9374; fax: +1 615 343 7797; e-mail: sten.vermund@vanderbilt.edu

Received 26 June, 2016

Revised 31 August, 2016

Accepted 12 September, 2016

Back to Top | Article Outline

Introduction

‘Treatment as Prevention (TasP)’ is a promising strategy for HIV prevention and intervention, as it can reduce the risk of HIV secondary transmission by suppressing viral replication [1,2]. The TasP strategy was first utilized to control the HIV epidemic among serodiscordant heterosexual couples in China. It has been expanded to Chinese MSM, as they have accounted for more than 20% of new cases in each year since 2013 [3]. However, there are several barriers to achieving the expected prevention effect. Maintaining good adherence to antiretroviral therapy (ART) is one of these major challenges [1]. A meta-analysis of 111 studies from both developed and developing countries reported an average of 71% of patients had ‘good’ (80% or more doses taken) adherence [95% confidence interval (CI): 66.0–75.3%] [4]. In China, recent reports suggest that about 77.6% (95% CI, 71.6–83.1%) of people living with HIV (PLHIV) on ART report adequate adherence (≥90%) [5]. Although the evidence is somewhat mixed with some reports of 80–90% of MSM reporting adequate adherence [6,7]. Suboptimal adherence can compromise the prevention effect of TasP strategy at the community level, and can lead to drug resistance and viral rebound at the individual level [8,9].

Mental health disorders may interrupt a patient's ability to adhere to treatment. Depression and anxiety are of particular concerns among PLHIV who are on ART. The prevalence of depression among PLHIV has been estimated 40% [4,10,11]. Anxiety is also common, 28% as reported in another meta-analysis [11]. In MSM with unknown HIV serostatus in China, the self-reported lifetime prevalence of depression and anxiety were 11.7 and 18.6% [12]. Studies have shown that PLHIV are twice likely to be depressed and/or anxious than comparable HIV-negative persons [13]. Hence, depression and anxiety would be expected to be more common among HIV-infected Chinese MSM.

Studies have showed that depression and anxiety are associated with poor adherence among PLHIV [4,14–17]. Little is known about their prevalence rates and effects on ART adherence among newly diagnosed PLHIV. We conducted this study to fill in these knowledge gaps, and test our hypothesis that depression and anxiety are associated with ‘imperfect’ adherence (at least one missing dose in the past 3 months) to ART among Chinese MSM with newly diagnosed HIV infections. Scaling-up treatment of depression and anxiety is a cost-effective global strategy with multiple health benefits [18], and our research addresses the extent to which benefits on ART adherence might accrue among newly diagnosed HIV-infected Chinese MSM.

Back to Top | Article Outline

Methods

Study design and population

The parent study (‘Multicomponent HIV Intervention Packages for Chinese MSM’ or China-MP3 project, ClinicalTrials.gov Identifier: NCT01904877) was a two-phase randomized clinical trial (RCT) of using peer counseling and short messaging services to increase HIV testing and linkage to care among HIV-infected MSM in comparison to the standard of care (SOC). SOC included linkage to care, HIV risk reduction counseling, ART referral, and other relevant medical services provided by local Centers for Disease Control and Prevention or hospitals in Beijing City. In addition to SOC, participants in the intervention arm received additional five sessions of face-to-face peer counseling and 32 text messages during the study period. A total of 455 HIV infections were newly identified among 3588 eligible MSM in Beijing, China in the phase I study, and 81% (367/455) of HIV-infected participants were successfully enrolled into the phase II of the study. We assessed the effects of depression and anxiety on ART adherence among a subgroup of MSM participants who initiated ART after HIV diagnosis.

Back to Top | Article Outline

Data collection

In the phase I study, we collected information on demographics, drug and alcohol use, and sexual behaviors, as well as laboratory data on HIV and syphilis serostatus. In the RCT, we measured entry to care, initiation of ART, adherence, and drug and alcohol use every 3 months. We also measured depression and anxiety [19], quality of life, self-efficacy [20], and stigma related to homosexuality [21] and HIV/AIDS [22] every 6 months.

Back to Top | Article Outline

Measurement of depression and anxiety

Depression and anxiety were measured by the Hospital Anxiety and Depression Scale (HADS) – a scale validated for identifying depression and anxiety in multiple populations across countries [23]. The HADS has seven items to measure depression, and another seven items for anxiety. The score of each item ranges from 0 to 3. Hence, the total scores for depression or anxiety range from 0 to 21 each. The thresholds for categorizing depression and anxiety are 7 and 11: a score of 0–7 is considered ‘normal’, 8–10 ‘borderline depression or anxiety’; and 11–21 ‘likely depression or anxiety’. Depression and anxiety are commonly used as categorical variables in clinical practice. To avoid categorization leading to low statistical power to detect the true difference by categorizing individuals with heterogeneous effects into the same group, we analyzed the data using both continuous and categorical variables.

Back to Top | Article Outline

Measurement of antiretroviral therapy adherence

Participants self-reported missing any ART doses in the past 3 months in the follow-up surveys. We categorized adherence as a binary outcome: ‘perfect’ adherence indicating not missing any dose, or ‘imperfect’ adherence meaning missing at least one dose. As participants initiated ART at varying time points, the number of measurements of ART adherence varied from 1 to 4 [median 4; interquartile range (IQR) 2–4] among participants.

Back to Top | Article Outline

Statistical analysis

We included 228 Chinese MSM who initiated ART after HIV diagnosis, and had at least one measurement of adherence during 12 months of follow-up. Depression and anxiety were also repeated measurements. Mixed-effect models were used to analyze the association between depression and anxiety and ART adherence. Measurements of depression and anxiety at RCT enrollment were adjusted in the model, and the next two measurements at 6 and 12 months were treated as time-varying covariates. As we did not measure depression and anxiety at 3 and 9 months, the measurements of ART adherence at RCT enrollment, 6 and 12 months were used in the mixed effects models. For the continuous depression and anxiety scores, restricted cubic splines were used, when the linearity assumption did not hold. A priori substantial knowledge guiding by causal graphs were utilized to determine potential confounding variables [24]. Drug and/or alcohol use can have an impact on depression and/or anxiety, and vice versa [25]. Hence, we had two sets of confounding variables. The first set included age, study intervention assignment, study site, education, social support, HIV-related stigma, and drug and alcohol use (Model-1). The second set included all listed variables except drug and alcohol use (Model-2). We used likelihood ratio test to test whether the study intervention arm (control vs. intervention) and/or HIV-related stigma were potential effect modifiers. All analyses were run using Stata 12.0 (StataCorp LP, College Station, Texas, USA).

Back to Top | Article Outline

Results

Demographics of study population

The median age of 228 eligible Chinese MSM was 28 years (IQR: 25–32). Most of them were of Han ethnicity (94%), single (86%), had received at least a college education (82%), and were employed (87%). Around half of our study population (49%) came from small cities or township/countryside. In total, 80% of participants did not have Beijing ‘hukou’ (registered household residence). The majority reported having healthcare insurance (58%), and being satisfied about the support received from family members and/or friends (74%). In the past 3 months, 37% of participants reported drug use, and 56% reported alcohol use. At baseline, the prevalence of likely or borderline depression was 43%, and likely or borderline anxiety was 49% (Table 1). The median score for baseline depression was 7 (IQR 4–10), and for anxiety was 7 (IQR 4–11) at baseline. Continuous depression and anxiety scores were highly correlated at baseline (correlation coefficient (r) = 0.85).

Table 1

Table 1

Back to Top | Article Outline

Antiretroviral therapy initiation and adherence

Among 367 enrolled Chinese MSM, 228 individuals (62%) started ART by the end of the RCT. Three of 228 participants initiated treatment after HIV diagnosis, but before enrollment in the RCT. The percentage of self-reported ‘perfect’ ART adherence was 92% (140/153) at 3 months follow-up, 89% (148/167) at 6 months, 88% (170/194) at 9 months, and 88% (167/189) at 12 months (Table 2). The number of ART initiators at each follow-up visit varied as per their initiation time points and missing visits. By the end of the study, 21% of our study participants missed at least one visit.

Table 2

Table 2

Back to Top | Article Outline

Depression and antiretroviral therapy adherence

There was insufficient evidence to conclude that the association between depression and the log-odds of depression was nonlinear (P > 0.05). We used the linear depression score in our models rather than restricted cubic splines. As intervention and HIV-related stigma were not effect modifiers in our analysis, they were treated as potentially confounding variables. Table 3 presents results of associations between depression and ART adherence. In the Model-l, we observed that a one-unit increase in depression score was associated with a 16% increase in the odds of reporting ‘imperfect’ ART adherence [adjusted odds ratio (aOR) 1.16; 95% CI 1.02–1.32]. The association was similar in the Model-2 (aOR 1.13; 95% CI 0.99–1.29).

Table 3

Table 3

When depression scores were collapsed into categories, all point estimates indicated that depression was likely to be a risk factor of self-reported ‘imperfect’ ART adherence in all models (Table 2). However, none of these associations was statistically significant. In the Model-1 and Model-2, likely depression had a relatively large effect on ART adherence in its magnitude of association, when compared with borderline depression.

Back to Top | Article Outline

Anxiety and antiretroviral therapy adherence

We used linear anxiety score in our analyses, as the linearity assumption held (Table 3). The likelihood ratio tests failed to identify intervention and HIV-related stigma as effect modifiers in our study. Hence, we treated them as potentially confounding variables. We found that a one-score increase in anxiety score was associated with a 17% increase (aOR: 1.17, 95% CI: 1.03, 1.33) in the odds of reporting ‘imperfect’ ART adherence in the Model-1. The result from Model-2 was similar to that from Model-1 (Table 2).

Results from models using the categorical designation of anxiety also suggested that anxiety was likely associated with ‘imperfect’ ART adherence. For likely anxiety, we observed a strong and significant association with the point estimates ranging from 4.79 to 4.83 in the Model-1 and Model-2. Individuals with borderline anxiety were 85% more likely to report ‘imperfect’ ART adherence than ones without anxiety, but this association was not significant in any model.

Back to Top | Article Outline

Discussion

Our study found that both depression and anxiety were risk factors for ‘imperfect’ ART adherence among Chinese MSM with newly diagnosed HIV infections. This is consistent with prior findings in PLHIV from a variety of venues and backgrounds [4,14,15]. A one-unit increase in the depression score was significantly associated with ‘imperfect’ ART adherence, and the association (aOR 1.16; 95% CI 1.02–1.31) was stronger than that reported previously from Brazil (aOR 1.04; 95% CI 1.01–1.06) [26]. We used HADS to measure depression among newly diagnosed Chinese MSM in our cohort study, whereas the Brazilian study used the Hamilton Rating Scale for Depression to assess depression in PLHIV in a cross-sectional study [26]. This may lead to the difference in the magnitude of the effect size. Even though we did not find significant associations between categorical depression and ART adherence, the point estimates (aOR varying from 1.74 to 1.80) suggested that depression (borderline or likely) was likely associated with ‘imperfect’ ART adherence.

For anxiety, a one-score increase was associated with a 17% increase in the odds of reporting ‘imperfect’ ART adherence (aOR 1.17; 95% CI 1.03–1.33). For the categorical anxiety analysis, we only found a significant association between ‘likely’ anxiety and ‘imperfect’ adherence to ART (aOR 4.79; 95% CI 1.12–20.50). The literature has also reported similar effects of depression and anxiety (categorical) on ‘imperfect’ adherence to ART [4,17]. Loss of statistical power in the categorical analysis could be a potential explanation for nonsignificant results with wide CIs. The weight of evidence from both continuous and categorical analyses supports the hypothesis that depression and anxiety are associated with lower ART adherence among newly diagnosed Chinese MSM, consistent with findings in other PLHIV.

Depression and anxiety measured right after HIV diagnosis can be a reflection of immediate health concerns. Unlike initiation that just needs a one-time effort, maintaining ART adherence takes a persistent effort. It is presumably hard for patients with sustained depression or anxiety to adhere to ART over months and years. Depressed and/or anxious individuals may lose interest in HIV care, and may be less capable in keeping to daily schedules.

Depression and anxiety are common among Chinese MSM with newly diagnosed HIV infections. The prevalence of depression and anxiety in our study population were similar to those reported in other studies with PLHIV [4,10,11]. However, our scale-based measurements revealed prevalence of depression and anxiety to be twice those reported among Chinese MSM with a HIV negative or unknown serostatus [12]. The proportion of MSM with ‘perfect’ ART adherence was around 90% in all four follow-up visits over 12 months, higher than that reported in HIV-infected people in several meta-analyses (77%) [4,10,11]. Although self-reported perfect ART adherence might be overestimated by self-report, other studies of ART adherence among Chinese MSM also reported a comparatively high proportion adhering to ART [7,12]. Education could be possible explanations for this favorable difference. Chinese MSM are a highly educated population with 80% having at least a college education [7,12,27]. Among Chinese PLHIV as a whole, less than 19% had a college degree [28]. In addition, better educated HIV-infected individuals are more likely to adhere to ART [29,30].

Our study's strengths include its longitudinal study design nested within a RCT. Both our exposure (depression and anxiety) and outcome (ART adherence) were repeated measurements, and we had a higher power to detect the true difference. All our study participants were enrolled in a short time interval after HIV diagnosis, which enabled us to draw inferences among MSM who recently learned of their HIV positive status.

There were also several limitations in our study. We recruited MSM from a single metropolitan city Beijing. We cannot generalize our finding to MSM in all of China. Further studies with representative samples are needed to replicate our findings. By the end of the study, 21% participants missed at least one visit. Our results can be either attenuated or overestimated because of missing visits. Reporting bias may be an issue, as adherence to ART was self-reported.

Early ART initiation and ‘perfect’ adherence to treatment in this newly diagnosed population are critical to achieve successful viral suppression and good treatment outcomes. ART adherence can also contribute to controlling the HIV epidemic among Chinese MSM through reduced infectiousness of HIV-infected persons. Depression and anxiety were associated with reporting ‘imperfect’ ART adherence. Psychiatrists or other qualified mental health professionals are needed to assess the severity of depression and anxiety, and to provide therapeutic advice to newly diagnosed HIV-infected MSM. Other medical conditions that may cause depression or anxiety should be investigated, especially if the history suggests that the HIV diagnosis was not the precipitant of the psychological symptoms. For MSM with mild or moderate depression and/or anxiety, peer counseling and support may help to deal with their symptoms. For severe cases, antidepressant or antianxiety medications may be given apart from peer counseling and support. Intensive early interventions targeting depression and anxiety, beyond routine counseling, may help improve ART adherence among newly diagnosed Chinese MSM.

Back to Top | Article Outline

Acknowledgements

The study was supported by grants from the United States National Institutes of Health under Award Numbers R01AI094562 and R34AI091446.

H.Q., J.T., and S.V. worked together to propose this study. J.T. did the statistical analysis, and drafted this manuscript. A.K., B.S., H.L., H.Q., K.A., S.V., Y.R., and Y.S. provided valuable comments and suggestions, and revised this manuscript.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012; 9:973.
2. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, et al Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010; 5:298.
3. Joint United Nations Programme on HIV/AIDS. China AIDS response progress report. 2015. Geneva: UNAIDS; 2015.
4. Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep 2014; 11:291–307.
5. Huan Z, Fuzhi W, Lu L, Min Z, Xingzhi C, Shiyang J. Comparisons of adherence to antiretroviral therapy in a high- risk population in china: a systematic review and meta-analysis. PLoS One 2016; 11:e0146659.
6. Zhou YF, Gao MX, Sun YH, Tang H, Fu Y. Nursing of AIDS patients under antiretroviral therapy among MSM and analysis of their psychological status. Chin J AIDS STD 2012; 18:746–748.
7. Qiao JK. Effect analysis of free antiretroviral treatment among MSM with AIDS in Yuncheng. Chin J AIDS STD 2014; 20:428–430.
8. Glass TR, Sterne JA, Schneider MP, De Geest S, Nicca D, Furrer H, et al Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS 2015; 29:2195–2200.
9. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112–1118.
10. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158:725–730.
11. Lowther K, Selman L, Harding R, Higginson IJ. Experience of persistent psychological symptoms and perceived stigma among people with HIV on antiretroviral therapy (ART): a systematic review. Int J Nurs Stud 2014; 51:1171–1189.
12. Yu L, Jiang C, Na J, Li N, Diao W, Gu Y, et al Elevated 12-month and lifetime prevalence and comorbidity rates of mood, anxiety, and alcohol use disorders in Chinese men who have sex with men. PLoS One 2013; 8:e50762.
13. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158:725–730.
14. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 2011; 58:181–187.
15. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav 2012; 16:2101–2118.
16. Panigrahi M, Swain TR, Mohanty S. Nonadherence to anti-HIV medication is associated with higher level of anxiety: experience from a tertiary care hospital of Odisha. Indian J Pharmacol 2015; 47:672–675.
17. Campos LN, Guimarães MD, Remien RH. Anxiety and depression symptoms as risk factors for nonadherence to antiretroviral therapy in Brazil. AIDS Behav 2010; 14:289–299.
18. Chisholm D, Sweeny K, Sheehan P, Rasmussen B, Smit F, Cuijpers P, et al Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016; 3:415–424.
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361–370.
20. Zhang JX, Schwarzer R. Measuring optimistic self-beliefs: a Chinese adaptation of the General Self-Efficacy Scale. Psychologia 1995; 38:174–181.
21. Neilands TB, Steward WT, Choi K-H. Assessment of stigma towards homosexuality in China: a study of men who have sex with men. Arch Sex Behav 2008; 37:838–844.
22. Steward WT, Herek GM, Ramakrishna J, Bharat S, Chandy S, Wrubel J, et al HIV-related stigma: adapting a theoretical framework for use in India. Soc Sci Med 2008; 67:1225–1235.
23. Brennan C, Worrall-Davies A, McMillan D, Gilbody S, House A. The Hospital Anxiety and Depression Scale: a diagnostic meta-analysis of case-finding ability. J Psychosom Res 2010; 69:371–378.
24. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002; 155:176–184.
25. Mackie CJ, Conrod P, Brady K. Depression and substance use. In: Drug abuse and addiction in medical illness: Springer; 2012; 275–283.
26. Tufano CS, Amaral RA, Cardoso LR, Malbergier A. The influence of depressive symptoms and substance use on adherence to antiretroviral therapy. A cross-sectional prevalence study. Sao Paulo Med J 2014; 133:179–186.
27. Tao J, Ruan Y, Yin L, Vermund SH, Shepherd BE, Shao Y, et al Sex with women among men who have sex with men in China: prevalence and sexual practices. AIDS Patient Care STDS 2013; 27:524–528.
28. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, et al Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011; 11:516–524.
29. Amico KR, Fisher WA, Cornman DH, Shuper PA, Redding CG, Konkle-Parker DJ, et al Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42:455–459.
30. Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, et al Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 2004; 8:141–150.

* Sten H. Vermund and Hongyan Lu and contributed equally to the writing of this article.

Keywords:

adherence; antiretroviral therapy; anxiety; China; depression; MSM; newly diagnosed HIV infections

Copyright © 2017 Wolters Kluwer Health, Inc.